The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Preventing Vertical Transmission of Hepatitis B virus

B형간염바이러스의 수직감염 예방

  • Choe, Won Hyeok (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Lee, June Sung (Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine)
  • 최원혁 (건국대학교 의학전문대학원 내과학교실) ;
  • 이준성 (인제대학교 의과대학 일산백병원 내과)
  • Published : 2014.11.01
⟨ Previous Next ⟩

Abstract

Vertical transmission of hepatitis B virus (HBV) is the main source of chronic infection in Korea, an HBV-endemic area, and chronically infected people are at high risk of developing liver cirrhosis or hepatocellular carcinoma. Thus, preventing vertical transmission is an important step in eradicating or reducing the burden of chronic HBV infection. However, despite passive-active immunoprophylaxis provided to infants, up to 10% of infants born to highly viremic mothers still become infected with HBV. Therefore, antiviral treatments or management protocols to reduce vertical transmission should be considered for highly viremic mothers and infants born to these mothers. Additionally, in-depth discussions with the mothers about the risks, benefits, and limitations of the current published data are essential. This article reviews the potential mechanisms of vertical transmission and current intervention strategies to prevent vertical transmission of HBV.

Keywords

References

  1. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-162. https://doi.org/10.3350/cmh.2012.18.2.109
  2. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993;253:197-201. https://doi.org/10.1098/rspb.1993.0102
  3. Kim JH, Kim JS, Lee JJ, et al. Survey of perinatal hepatitis B virus transmission after Korean National Prevention Program in a tertiary hospital. Korean J Intern Med 2014;29:307-314. https://doi.org/10.3904/kjim.2014.29.3.307
  4. Patton H, Tran TT. Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol 2014;11:402-409. https://doi.org/10.1038/nrgastro.2014.30
  5. Pan CQ, Duan ZP, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012;10:452-459. https://doi.org/10.1016/j.cgh.2011.10.041
  6. Ma L, Alla NR, Li X, Mynbaev OA, Shi Z. Mother-to-child transmission of HBV: review of current clinical management and prevention strategies. Rev Med Virol 2014 Jun 23[Epub]. http://dx.doi.org/10.1002/rmv.1801.
  7. Bleich LM, Swenson ES. Prevention of neonatal hepatitis B virus transmission. J Clin Gastroenterol 2014;48:765-772. https://doi.org/10.1097/MCG.0000000000000115
  8. Wong F, Pai R, Van Schalkwyk J, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Ann Hepatol 2014;13:187-195.
  9. Park JS, Pan C. Current recommendations of managing HBV infection in preconception or pregnancy. Front Med 2014;8:158-165. https://doi.org/10.1007/s11684-014-0340-4
  10. Lopez M1, Coll O. Chronic viral infections and invasive procedures: risk of vertical transmission and current recommendations. Fetal Diagn Ther 2010;28:1-8. https://doi.org/10.1159/000309155
  11. Yi W, Pan CQ, Hao J, et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014;60:523-529. https://doi.org/10.1016/j.jhep.2013.11.008
  12. Degli Esposti S, Shah D. Hepatitis B in pregnancy: challenges and treatment. Gastroenterol Clin North Am 2011;40:355-372. https://doi.org/10.1016/j.gtc.2011.03.005
  13. Zhang L, Gui X, Fan J, et al. Breast feeding and immunoprophylaxis efficacy of mother-to-child transmission of hepatitis B virus. J Matern Fetal Neonatal Med 2014;27:182-186. https://doi.org/10.3109/14767058.2013.806901
  14. Wong VC, Lee AK, Ip HM. Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant. Br J Obstet Gynaecol 1980;87:958-965. https://doi.org/10.1111/j.1471-0528.1980.tb04458.x
  15. Mitsuda T, Yokota S, Mori T, et al. Demonstration of mother- to-infant transmission of hepatitis B virus by means of polymerase chain reaction. Lancet 1989;2:886-888.
  16. Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012;142:773-781. https://doi.org/10.1053/j.gastro.2011.12.035
  17. Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013;59:24-30. https://doi.org/10.1016/j.jhep.2013.02.015
  18. Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus--a systematic review. Virol J 2008;5:100. https://doi.org/10.1186/1743-422X-5-100
  19. Pan CQ, Zou HB, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol 2013;11:1349-1355. https://doi.org/10.1016/j.cgh.2013.04.026
  20. Senise J, Bonafe S, Castelo A. The management of HIV-infected pregnant women. Curr Opin Obstet Gynecol 2012;24:395-401. https://doi.org/10.1097/GCO.0b013e328359f11e
  21. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal- infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J (Engl) 2002;115:1510-1512.
  22. Zheng Y, Lu Y, Ye Q, et al. Should chronic hepatitis B mothers breastfeed? a meta analysis. BMC Public Health 2011;11:502. https://doi.org/10.1186/1471-2458-11-502
  23. Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;2:740-741.
  24. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002;99:1049-1052. https://doi.org/10.1016/S0029-7844(02)02000-8
  25. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma- derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004;40:1415-1420. https://doi.org/10.1002/hep.20490
  26. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185. https://doi.org/10.1016/j.jhep.2012.02.010
  27. Pan CQ, Lee HM. Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis 2013;33:138-146. https://doi.org/10.1055/s-0033-1345718
  28. Dusheiko G. Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis? Lancet 2012;379:2019-2021. https://doi.org/10.1016/S0140-6736(11)61182-3
  29. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo- controlled study. J Viral Hepat 2009;16:94-103. https://doi.org/10.1111/j.1365-2893.2008.01056.x
  30. van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000;32:1040-1041. https://doi.org/10.1016/S0168-8278(00)80112-9
  31. Sarkar M, Terrault NA. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology 2014;60:448-451. https://doi.org/10.1002/hep.27145
  32. Wu Q, Huang H, Sun X, et al. Telbivudine prevents vertical transmission of hepatitis B virus from women high viral loads: a prospective long-term study. Clin Gastroenterol Hepatol 2014 Sep 20[Epub]. http://dx.doi.org/10.1016/j.cgh.2014.08.043.
  33. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology 2014;60:468-476.
  34. Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013;19:9377-9382. https://doi.org/10.3748/wjg.v19.i48.9377
  35. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014;61:502-507. https://doi.org/10.1016/j.jhep.2014.04.038
  36. Tsai PJ, Chang A, Yamada S, Tsai N, Bartholomew ML. Use of tenofovir disoproxil fumarate in highly viremic, Hepatitis B mono-infected pregnant women. Dig Dis Sci 2014 Jun 5[Epub].

Cited by

  1. Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea vol.16, pp.None, 2018, https://doi.org/10.1186/s12962-018-0088-9